2,4-二氯-3-硝基吡啶-6-羧酸 | 850544-26-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,4-二氯-3-硝基吡啶-6-羧酸
• 英文名称: 2,4-dichloro-3-nitropyridine-6-carboxylic acid
• 英文别名: 4,6-dichloro-5-nitropicolinic acid；4,6-dichloro-5-nitropyridine-2-carboxylic acid；2-carboxy-4,6-dichloro-5-nitropyridine；4,6-Dichloro-5-nitro-2-pyridinecarboxylic acid
• CAS: 850544-26-2
• 化学式: C₆H₂Cl₂N₂O₄
• 分子量: 236.999
• InChiKey: ZYXYWPPPPRSSDN-UHFFFAOYSA-N

物化性质

• 熔点：
  137-139 °C
• 沸点：
  421.1±45.0 °C(Predicted)
• 密度：
  1.810±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-二氯-3-硝基吡啶-6-羧酸 在 platinum(IV) oxide 吡啶 、 盐酸 、 硫酸 、 氨 、 氢气 作用下， 以 甲醇 、 氯仿 为溶剂， 103.0 ℃ 、1.1 MPa 条件下， 反应 75.5h， 生成 methyl 5-acetylamino-4,6-diaminopyridine-2-carboxylate hydrochloride
  参考文献：
  名称：

  Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase

  摘要：

  Based upon the activity and X-ray crystallographic studies of tri-substituted benzene derivatives containing carboxylic acid, acetamido and guanidine groups, we investigated the effect of the fourth substituent to fulfill the fourth pocket of neuraminidase enzyme. The groups selected as fourth substituents were hydroxymethyl, hydroxyethyl, oxime and amino. These tetra-substituted benzene derivatives were synthesized and evaluated for neuraminidase inhibitory activity. All these compounds were found to have poorer IC50 values than the tri-substituted compounds. Further, benzene ring was replaced by pyridine ring and di, tri and tetra-substituted pyridine derivatives were synthesized. The activity of the pyridine derivatives was comparable to benzene derivatives. The fourth substituent seems to disturb the binding of the other three substituents, so the activity is reduced as compared to trisubstituted benzene and pyridine derivatives. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.01.042
• 作为产物：
  描述：

  2,4-dichloro-6-[β-(N,N-dimethylamino)vinyl]-3-nitropyridine 在 potassium permanganate 、 potassium carbonate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 5.5h， 以49%的产率得到2,4-二氯-3-硝基吡啶-6-羧酸
  参考文献：
  名称：

  Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase

  摘要：

  Based upon the activity and X-ray crystallographic studies of tri-substituted benzene derivatives containing carboxylic acid, acetamido and guanidine groups, we investigated the effect of the fourth substituent to fulfill the fourth pocket of neuraminidase enzyme. The groups selected as fourth substituents were hydroxymethyl, hydroxyethyl, oxime and amino. These tetra-substituted benzene derivatives were synthesized and evaluated for neuraminidase inhibitory activity. All these compounds were found to have poorer IC50 values than the tri-substituted compounds. Further, benzene ring was replaced by pyridine ring and di, tri and tetra-substituted pyridine derivatives were synthesized. The activity of the pyridine derivatives was comparable to benzene derivatives. The fourth substituent seems to disturb the binding of the other three substituents, so the activity is reduced as compared to trisubstituted benzene and pyridine derivatives. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.01.042

文献信息

• [EN] PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6<br/>[FR] CARBOXAMIDES HÉTÉROAROMATIQUES SUBSTITUÉS PAR PIPÉRIDINYLE ET PIPÉRAZINYLE EN TANT QUE MODULATEURS DE GPR6
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2018183145A1

  公开（公告）日：2018-10-04

  Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.

  本公开涉及公式1的化合物及其药用可接受的盐，其中L、R4、R5、R8、R10、R11、X1、X2、X3、X9、X12和Z在规范中定义。本公开还涉及制备公式1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与GPR6相关的疾病、紊乱和症状的用途。
• FUSED PYRIDINE DERIVATIVES
  申请人：Huang Zhenhua

  公开号：US20120289497A1

  公开（公告）日：2012-11-15

  Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R 1 , R 2 , R 3 , Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.

  揭示了作为一般式(I)显示的融合吡啶衍生物以及它们的药用可接受盐、立体异构体或溶剂化物，属于药物技术领域。在式(I)中，R1、R2、R3、Q、X和Y的取代基的定义如描述中所述。还揭示了该化合物的制备方法、包含该化合物的药物组合物以及用于制造治疗和/或预防非胰岛素依赖性糖尿病、高血糖、高脂血症和胰岛素抵抗的药物的用途。
• Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
  作者：Chutian Shu、Hu Ge、Michael Song、Jyun-hong Chen、Huimin Zhou、Qu Qi、Feng Wang、Xifeng Ma、Xiaolei Yang、Genyan Zhang、Yanwei Ding、Dapeng Zhou、Peng Peng、Cheng-kon Shih、Jun Xu、Frank Wu

  DOI：10.1021/ml5001905

  日期：2014.8.14

  We report our discovery of a novel series of potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Starting from a lead identified by scaffold-hopping approach, our discovery and development efforts were focused on exploring structure-activity relationships, optimizing pharmacokinetic profile, improving in vitro and in vivo efficacy, and evaluating safety profile. The selected candidate

  我们报告了我们发现的一系列新型的有效和选择性二肽基肽酶IV（DPP-4）抑制剂。从通过脚手架跳跃方法确定的线索开始，我们的发现和开发工作集中在探索结构与活性之间的关系，优化药代动力学特征，改善体外和体内功效以及评估安全性特征。选定的候选人伊米列汀目前正在接受临床试验。
• GLP-1R agonists and uses thereof
  申请人：QILU REGOR THERAPEUTICS INC.

  公开号：US10844049B2

  公开（公告）日：2020-11-24

  The invention described herein provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

  本发明提供了式（I）化合物及其药物组合物、 用于治疗 2 型糖尿病、糖尿病前期、肥胖症、非酒精性脂肪肝、非酒精性脂肪性肝炎和心血管疾病等。
• WO2020103815A5
  申请人：——

  公开号：WO2020103815A5

  公开（公告）日：2022-11-24